Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting

被引：5
|
作者：
Kim, Hyun Jung [1 ,2 ,3 ]
机构：
[1] Kookmin Univ, Dept Biopharmaceut Chem, Seoul 02707, South Korea
[2] Kookmin Univ, Sch Appl Chem, Seoul 02707, South Korea
[3] Kookmin Univ, Antibody Res Inst, Seoul 02707, South Korea
来源：
MEDICINA-LITHUANIA | 2022年 / 58卷 / 05期
基金：
新加坡国家研究基金会;
关键词：
hepatocyte growth factor; c-MET; ovarian cancer; humanized monoclonal antibody; anti-cancer; therapeutics; HEPATOCYTE GROWTH-FACTOR; RECURRENT EPITHELIAL OVARIAN; RECEPTOR TYROSINE KINASE; PHASE-II EVALUATION; C-MET; SCATTER FACTOR; FALLOPIAN-TUBE; MESENCHYMAL TRANSITION; FACTOR/SCATTER FACTOR; CLINICAL-SIGNIFICANCE;
D O I：
10.3390/medicina58050649
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics.
引用
收藏
页数：12
相关论文
共 50 条
  • [1] Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction
    Youngjoo Kwon
    Andrew K. Godwin
    Reproductive Sciences, 2017, 24 : 494 - 501
  • [2] Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction
    Kwon, Youngjoo
    Godwin, Andrew K.
    REPRODUCTIVE SCIENCES, 2017, 24 (04) : 494 - 501
  • [3] Targeting HGF/c-MET Axis in Pancreatic Cancer
    Pothula, Srinivasa P.
    Xu, Zhihong
    Goldstein, David
    Pirola, Romano C.
    Wilson, Jeremy S.
    Apte, Minoti, V
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (23) : 1 - 18
  • [4] Antibody targeting of the HGF/c-Met pathway
    Bottaro, D. P.
    ANNALS OF ONCOLOGY, 2008, 19 : 22 - 22
  • [5] The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches
    Hu, Chi-Tan
    Wu, Jia-Ru
    Cheng, Chuan-Chu
    Wu, Wen-Sheng
    CANCERS, 2017, 9 (06):
  • [6] Therapeutic targeting of c-Met in ovarian clear cell carcinoma
    Yoon, A.
    Lee, J. W.
    Lee, Y. Y.
    Kim, T. J.
    Kim, W. Y.
    Kim, B. G.
    Bae, D. S.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 134 - 134
  • [7] Current advances of targeting HGF/c-Met pathway in gastric cancer
    Anestis, Aristomenis
    Zoi, Ilianna
    Karamouzis, Michalis V.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (12)
  • [8] Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer
    Pothula, Srinivasa P.
    Xu, Zhihong
    Goldstein, David
    Merrett, Neil
    Pirola, Romano C.
    Wilson, Jeremy S.
    Apte, Minoti V.
    ONCOTARGET, 2017, 8 (44) : 76722 - 76739
  • [9] Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
    Miranda, Oshin
    Farooqui, Mariya
    Siegfried, Jill M.
    CANCERS, 2018, 10 (09)
  • [10] HGF/c-MET Targeted Therapeutics: Novel Strategies for Cancer Medicine
    Yap, Timothy A.
    Sandhu, Shahneen K.
    Alam, Salma M.
    de Bono, Johann S.
    CURRENT DRUG TARGETS, 2011, 12 (14) : 2045 - 2058
12345